Skip to main navigation
Madrigal Pharmaceuticals Madrigal Pharmaceuticals.
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Our Medicine
  • NASH
    • Overview
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
    • Core Values
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
Search
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Our Medicine
  • NASH
    • Overview
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
    • Core Values
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Stock Information
  • Corporate Governance
  • FAQs
  • Email Alerts

Mayank Mamtani

B Riley FBR

    Madrigal’s ambitious research programs led to the first FDA-approved treatment in NASH.

    Learn More
    Madrigal Pharmaceuticals. Logo

    Madrigal Pharmaceuticals

    200 Barr Harbor Drive,
    Suite 200

    West Conshohocken,
    Pennsylvania 19428

    • About Us
    • Our Programs
    • NASH
    • Investors & Media
    • Careers
    • Contact
    Madrigal Pharmaceuticals
    • Terms of Use
    • Privacy
    • Cookies
    • ETHICS and COMPLIANCE
    • TRANSPARENCY
    ©2025 Madrigal Pharmaceuticals. All rights reserved.